Novavax (NVAX) Receivables - Other (2020 - 2025)
Novavax (NVAX) has 12 years of Receivables - Other data on record, last reported at $10.8 million in Q4 2025.
- For Q4 2025, Receivables - Other rose 100.0% year-over-year to $10.8 million; the TTM value through Dec 2025 reached $10.8 million, up 100.0%, while the annual FY2025 figure was $10.8 million, 100.0% up from the prior year.
- Receivables - Other reached $10.8 million in Q4 2025 per NVAX's latest filing, up from $5.2 million in the prior quarter.
- Across five years, Receivables - Other topped out at $68.0 million in Q3 2022 and bottomed at $200000.0 in Q1 2024.
- Average Receivables - Other over 5 years is $26.1 million, with a median of $25.0 million recorded in 2021.
- Peak YoY movement for Receivables - Other: plummeted 99.53% in 2024, then surged 2950.0% in 2025.
- A 5-year view of Receivables - Other shows it stood at $35.3 million in 2021, then dropped by 18.98% to $28.6 million in 2022, then tumbled by 62.24% to $10.8 million in 2023, then tumbled by 50.0% to $5.4 million in 2024, then soared by 100.0% to $10.8 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Other were $10.8 million in Q4 2025, $5.2 million in Q3 2025, and $5.3 million in Q2 2025.